Autolus Therapeutics plc (6A3A) - Total Liabilities

Latest as of December 2025: €410.94 Million EUR ≈ $480.43 Million USD

Based on the latest financial reports, Autolus Therapeutics plc (6A3A) has total liabilities worth €410.94 Million EUR (≈ $480.43 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Autolus Therapeutics plc (6A3A) equity growth momentum to track the company's year-over-year net asset growth rate.

Autolus Therapeutics plc - Total Liabilities Trend (2017–2025)

This chart illustrates how Autolus Therapeutics plc's total liabilities have evolved over time, based on quarterly financial data.

Autolus Therapeutics plc Competitors by Total Liabilities

The table below lists competitors of Autolus Therapeutics plc ranked by their total liabilities.

Company	Country	Total Liabilities
Rice Acquisition Corporation 3 NYSE:KRSP	USA	$16.22 Million
Xunlei Ltd Adr NASDAQ:XNET	USA	$234.06 Million
BrasilAgro - Companhia Brasileira de Propriedades Agrícolas SA:AGRO3	Brazil	R$1.72 Billion
Studio City International Holdings Ltd NYSE:MSC	USA	$2.16 Billion
Zhejiang Giuseppe Garment Co Ltd SHE:002687	China	CN¥473.05 Million
Padini Holdings Bhd KLSE:7052	Malaysia	RM841.07 Million
Hotel Majestic Cannes PA:MLHMC	France	€33.61 Million
Jiangsu Tongda Power Technology Co Ltd SHE:002576	China	CN¥729.83 Million

Liability Composition Analysis (2017–2025)

This chart breaks down Autolus Therapeutics plc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Autolus Therapeutics plc market capitalisation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	5.94	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	2.31	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.70	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Autolus Therapeutics plc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Autolus Therapeutics plc (2017–2025)

The table below shows the annual total liabilities of Autolus Therapeutics plc from 2017 to 2025.

Year	Total Liabilities	Change
2025-12-31	€410.94 Million ≈ $480.43 Million	+15.63%
2024-12-31	€355.40 Million ≈ $415.50 Million	+34.67%
2023-12-31	€263.91 Million ≈ $308.54 Million	+37.74%
2022-12-31	€191.60 Million ≈ $224.00 Million	+107.72%
2021-12-31	€92.24 Million ≈ $107.84 Million	+9.54%
2020-12-31	€84.20 Million ≈ $98.44 Million	+72.93%
2019-12-31	€48.69 Million ≈ $56.93 Million	+174.49%
2018-12-31	€17.74 Million ≈ $20.74 Million	+192.69%
2017-12-31	€6.06 Million ≈ $7.09 Million	--

About Autolus Therapeutics plc

F:6A3A Germany Biotechnology

Market Cap

$519.62 Million

€444.46 Million EUR

Market Cap Rank

#13867 Global

#1415 in Germany

Share Price

€1.67

Change (1 day)

+16.78%

52-Week Range

€1.06 - €2.10

All Time High

€40.10